10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
New Jersey, USA-based Regeneron Pharmaceuticals has kicked off its first trial of REGN-COV2, an antibody combo for the prevention and treatment of COVID-19. 12 June 2020
New results from the NURTURE study show ongoing benefits for people with spinal muscular atrophy (SMA), when treated with Spinraza (nusinersen). 12 June 2020
The European Medicines Agency has validated the marketing authorization application (MAA) for tralokinumab, an investigational product for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) under development by privately-held Danish dermatology specialist LEO Pharma. 12 June 2020
A strategic licensing agreement has been reached between Stockholm’s Swedish Orphan Biovitrum and Massachusetts-based Selecta Biosciences. 12 June 2020
In its first full acquisition in the last couple of years, Danish diabetes care giant Novo Nordisk (NOV: N) today announced that it has entered into a definitive agreement to buy Corvidia Therapeutics, a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. 11 June 2020
Following the rapid progress made by AstraZeneca, another COVID-19 vaccine candidate is advancing apace, with Moderna’s option mRNA-1273 due to enter Phase III testing next month. 11 June 2020
While there are re-purposed drugs in use for the treatment of COVID-19, the first that was designed specifically for the virus has just entered production. 11 June 2020
On June 10, 2020, the US Food and Drug Administration approved Opdivo (nivolumab) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. 11 June 2020
The US Food and Drug Administration has approved a label update for Beovu (brolucizumab) to include additional safety information regarding retinal vasculitis and retinal vascular occlusion. 11 June 2020
A new “BioShield Program” has been launched by Orgenesis, aimed at accelerating the discovery of antibodies to combat viral infections like COVID-19. 11 June 2020
Danish biotech company Genmab closed 4% higher at the end of Wednesday’s trading after announcing an oncology collaboration with US drugmaker AbbVie. 10 June 2020
San Diego, USA-based biotech DelMar Pharmaceuticals’ shot up 20% pre-market today, as it revealed the signing of a definitive merger agreement with Adgero Biopharmaceuticals, a privately held biopharmaceutical company focused on the development of its late-stage photodynamic therapy platform for the treatment of serious cutaneous oncology indications. 10 June 2020
A company formed as a spinout from Cancer Research UK-funded science at The Institute of Cancer Research (ICR), London, has been publicly launched. 10 June 2020
The European Commission has granted approval for a label extension on Kalydeco (ivacaftor), the only drug approved in Europe to treat the underlying cause of cystic fibrosis. 10 June 2020
Israel-based biotech RedHill Biopharma has submitted a Clinical Trial Application (CTA) with the Ministry of Health of the Russian Federation for a Phase II/III clinical study evaluating opaganib (trade name Yeliva) in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia. 10 June 2020
Japanese pharma major Takeda is to in-license a microbiome remodeling program from Swiss company Debiopharm to develop new treatments for gastrointestinal (GI) disorders. 10 June 2020
Complementing its pioneering work on a COVID-19 vaccine, British drugmaker AstraZeneca has announced progress in the development of an antibody cocktail to treat infected people. 10 June 2020
Shares of Oxford, UK based e-therapeutics (ere up 5.7% at 18.15 pence by late morning, after the company revealed a collaboration agreement with Belgium’s Galapagos to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary fibrosis (IPF) and potentially in other fibrotic indications. 10 June 2020
The Phase III KEYNOTE-361 trial evaluating Keytruda (pembrolizumab), in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpoints of overall survival (OS) or progression-free survival (PFS), compared with standard of care chemotherapy. 10 June 2020
Another major drug trial for a possible COVID-19 therapeutic is to launch in the UK, testing namilumab (IZN-101), an antibody currently in a Phase IIb study in rheumatoid arthritis. 10 June 2020
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024